GLP1R and Parkinson disease: Therefore, repurposing of FDA-approved GLP-1R agonists with improved pharmacokinetics, could be potential therapeutic strategy for the treatment of neurodegenerative diseases associated with microgliosis and reactive astrogliosis, including AD, PD, PSD, and VCID.